Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer
Xiaoling Li(University of Science and Technology of China), Ping Mu(Yale Cancer Center)
Cited by 47
Related Papers
Neoantigen vaccine: an emerging tumor immunotherapy
|Molecular Cancer|2019|718
Circular RNAs in human cancer
|Molecular Cancer|2017|527
Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer
|Cancer Cell|2020|252
Natural killer group 2D receptor and its ligands in cancer immune escape
|Molecular Cancer|2019|241
Effects of tumor metabolic microenvironment on regulatory T cells
|Molecular Cancer|2018|185